Solid Biosciences Q2 net loss $18.7M; cash $249M; next IGNITE DMD dose in Q4 2021

Solid Biosciences Inc.

2022-Q2 EPS reported -$0.35

Collaboration revenue of $3.6M vs $0 in prior year from Ultragenyx deal.
R&D expenses $15.5M (up from $13.4M) driven by SGT-001 manufacturing and clinical costs.
Cash, cash equivalents and securities $249M as of June 30, 2021; runway into Q4 2022.
IGNITE DMD trial: next patient dosing anticipated Q4 2021; no new safety findings in patients 1-8 over 90 days to >3 years.
Targeting IND submission for next-generation SGT-003 in early-2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.